{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T13:56:29Z","timestamp":1793973389371,"version":"4.8.0"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T00:00:00Z","timestamp":1767052800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T00:00:00Z","timestamp":1767052800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["No. 82403017 and No. 82272990"],"award-info":[{"award-number":["No. 82403017 and No. 82272990"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Diabetol Metab Syndr"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background\/aims<\/jats:title>\n                    <jats:p>Metabolic dysfunction-associated steatotic liver disease (MASLD) is a common but understudied disease in adolescents. We aimed to estimate the updated prevalence of MASLD and related fibrosis among US adolescents using transient elastography.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This study analyzed data from the National Health and Nutrition Examination Survey 2017 to March 2020 and August 2021 to August 2023 among adolescents ages 12-19 years. Steatotic liver disease was assessed using the median controlled attenuation parameter (CAP) and fibrosis by median liver stiffness measurement.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 2588 participants were included in the analysis (mean [SD] age, 15.4 [2.3] years; 1366 male participants [52.8%]). The overall age-adjusted prevalence of MASLD was 21.0% (95% CI: 19.1\u201323.0) using a CAP threshold of \u2265 248 dB\/m and 16.1% (95% CI: 14.4\u201317.8) using \u2265 263 dB\/m. The prevalence of MASLD-related fibrosis was 9.0% and 9.7% using CAP thresholds of 248 dB\/m and 263 dB\/m, respectively. Higher prevalence of MASLD and fibrosis was observed among adolescents with overweight, obesity, and prediabetes. Between the two survey cycles, the age-standardized prevalence of MASLD remained stable, with a non-significant decline observed in the prevalence of fibrosis. Multivariable analysis identified male sex, non-Hispanic Asian ethnicity, increased waist circumference, overweight, and obesity as independent risk factors for MASLD, while waist circumference was the only independent factor associated with MASLD-related fibrosis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In this cross-sectional study, MASLD and MASLD-related fibrosis were highly prevalent among US adolescents, with significant disparities observed by sex, race, and ethnicity. These findings highlight the substantial burden of MASLD in the adolescent population and underscore the need for continued public health focus.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Graphical abstract<\/jats:title>\n                  <\/jats:sec>","DOI":"10.1186\/s13098-025-02024-9","type":"journal-article","created":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T00:34:17Z","timestamp":1767054857000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Prevalence of MASLD and fibrosis assessed by transient elastography in U.S. adolescents: insights from NHANES 2017-2023"],"prefix":"10.1186","volume":"17","author":[{"given":"Jialin","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junlong","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiyu","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Lyu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peiyao","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiejun","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bonan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fuda","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ge","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kangmin","family":"Zhuang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aimin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ka Fai","family":"To","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,30]]},"reference":[{"issue":"3","key":"2024_CR1","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1016\/j.jhep.2023.04.036","volume":"79","author":"VWS Wong","year":"2023","unstructured":"Wong VWS, Ekstedt M, Wong GLH, Hagstr\u00f6m H. Changing epidemiology, global trends and implications for outcomes of NAFLD. J Hepatol. 2023;79(3):842\u201352. https:\/\/doi.org\/10.1016\/j.jhep.2023.04.036.","journal-title":"J Hepatol"},{"key":"2024_CR2","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1136\/gutjnl-2020-320622","volume":"69","author":"G Targher","year":"2020","unstructured":"Targher G, Byrne CD, Tilg H. Nafld and increased risk of cardiovascular disease: clinical associations, pathophysiological mechanisms and pharmacological implications. Gut. 2020;69:1691\u2013705. https:\/\/doi.org\/10.1136\/gutjnl-2020-320622.","journal-title":"Gut"},{"key":"2024_CR3","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1136\/gutjnl-2022-328105","volume":"72","author":"TG Simon","year":"2023","unstructured":"Simon TG, et al. Cardiovascular disease risk in paediatric and young adult non-alcoholic fatty liver disease. Gut. 2023;72:573\u201380. https:\/\/doi.org\/10.1136\/gutjnl-2022-328105.","journal-title":"Gut"},{"key":"2024_CR4","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1136\/jitc-2022-004666","volume":"29","author":"J Wu","year":"2023","unstructured":"Wu J, et al. Inflammation-related nomogram for predicting survival of patients with unresectable hepatocellular carcinoma received conversion therapy. World J Gastroenterol. 2023;29:125\u201336. https:\/\/doi.org\/10.1136\/jitc-2022-004666.","journal-title":"World J Gastroenterol"},{"key":"2024_CR5","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.1097\/HEP.0000000000000520","volume":"78","author":"ME Rinella","year":"2023","unstructured":"Rinella ME, et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Hepatology. 2023;78:1966\u201386. https:\/\/doi.org\/10.1097\/HEP.0000000000000520.","journal-title":"Hepatology"},{"key":"2024_CR6","doi-asserted-by":"publisher","first-page":"e82","DOI":"10.1016\/j.jhep.2023.09.030","volume":"80","author":"T Yang","year":"2024","unstructured":"Yang T, Yin J, Li J, Wang Q. The influence of different combinations of cardiometabolic risk factors on the prevalence of MASLD and risk of advanced fibrosis deserves attention. J Hepatol. 2024;80:e82\u20135. https:\/\/doi.org\/10.1016\/j.jhep.2023.09.030.","journal-title":"J Hepatol"},{"key":"2024_CR7","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1111\/obr.12407","volume":"17","author":"L Li","year":"2016","unstructured":"Li L, et al. Obesity is an independent risk factor for non-alcoholic fatty liver disease: evidence from a meta-analysis of 21 cohort studies. Obes Rev. 2016;17:510\u20139. https:\/\/doi.org\/10.1111\/obr.12407.","journal-title":"Obes Rev"},{"key":"2024_CR8","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.jpeds.2018.11.021","volume":"207","author":"EL Yu","year":"2019","unstructured":"Yu EL, et al. Prevalence of nonalcoholic fatty liver disease in children with obesity. J Pediatr. 2019;207:64\u201370. https:\/\/doi.org\/10.1016\/j.jpeds.2018.11.021.","journal-title":"J Pediatr"},{"key":"2024_CR9","doi-asserted-by":"publisher","first-page":"e1458","DOI":"10.1210\/clinem\/dgae553","volume":"110","author":"X Zheng","year":"2025","unstructured":"Zheng X, et al. Prevalence of metabolic dysfunction-associated steatotic liver disease and cardiometabolic risk factor in US adolescents. J Clin Endocrinol Metab. 2025;110:e1458\u201365. https:\/\/doi.org\/10.1210\/clinem\/dgae553.","journal-title":"J Clin Endocrinol Metab"},{"key":"2024_CR10","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/j.jhep.2020.03.044","volume":"73","author":"D Ji","year":"2020","unstructured":"Ji D, et al. Non-alcoholic fatty liver diseases in patients with COVID-19: a retrospective study. J Hepatol. 2020;73:451\u20133. https:\/\/doi.org\/10.1016\/j.jhep.2020.03.044.","journal-title":"J Hepatol"},{"key":"2024_CR11","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.m606","volume":"368","author":"XW Xu","year":"2020","unstructured":"Xu XW, et al. Clinical findings in a group of patients infected with the 2019 novel coronavirus (SARS-Cov-2) outside of Wuhan, China: retrospective case series. BMJ. 2020;368:m606. https:\/\/doi.org\/10.1136\/bmj.m606.","journal-title":"BMJ"},{"key":"2024_CR12","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1210\/endrev\/bnad032","volume":"45","author":"C Conte","year":"2024","unstructured":"Conte C, Cipponeri E, Roden M. Diabetes mellitus, energy metabolism, and COVID-19. Endocr Rev. 2024;45:281\u2013308. https:\/\/doi.org\/10.1210\/endrev\/bnad032.","journal-title":"Endocr Rev"},{"key":"2024_CR13","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/S2213-8587(22)00355-2","volume":"11","author":"E Xu","year":"2023","unstructured":"Xu E, Xie Y, Al-Aly Z. Risks and burdens of incident dyslipidaemia in long COVID: a cohort study. Lancet Diabetes Endocrinol. 2023;11:120\u20138. https:\/\/doi.org\/10.1016\/S2213-8587(22)00355-2.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2024_CR14","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/S2213-8587(23)00351-0","volume":"12","author":"J Hartmann-Boyce","year":"2024","unstructured":"Hartmann-Boyce J, et al. The impact of the COVID-19 pandemic and associated disruptions in health-care provision on clinical outcomes in people with diabetes: a systematic review. Lancet Diabetes Endocrinol. 2024;12:132\u201348. https:\/\/doi.org\/10.1016\/S2213-8587(23)00351-0.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2024_CR15","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2016632118","author":"O Giuntella","year":"2021","unstructured":"Giuntella O, Hyde K, Saccardo S, Sadoff S. Lifestyle and mental health disruptions during COVID-19. Proc Natl Acad Sci U S A. 2021. https:\/\/doi.org\/10.1073\/pnas.2016632118.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2024_CR16","doi-asserted-by":"publisher","DOI":"10.1111\/liv.16112","volume":"45","author":"W Wu","year":"2025","unstructured":"Wu W, Guo Y, Li Q, Jia C. Exploring the potential of large language models in identifying metabolic dysfunction-associated steatotic liver disease: a comparative study of non-invasive tests and artificial intelligence-generated responses. Liver Int. 2025;45:e16112. https:\/\/doi.org\/10.1111\/liv.16112.","journal-title":"Liver Int"},{"key":"2024_CR17","doi-asserted-by":"crossref","unstructured":"Klein RJ, Schoenborn CA. Age adjustment using the 2000 projected U.S. population. Healthy People 2010 Stat Notes; 2001.","DOI":"10.1037\/e583772012-001"},{"key":"2024_CR18","doi-asserted-by":"publisher","first-page":"2005","DOI":"10.1002\/hep.25762","volume":"55","author":"N Chalasani","year":"2012","unstructured":"Chalasani N, et al. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology. 2012;55:2005\u201323. https:\/\/doi.org\/10.1002\/hep.25762.","journal-title":"Hepatology"},{"key":"2024_CR19","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1080\/00365521.2022.2041085","volume":"57","author":"Y Zhao","year":"2022","unstructured":"Zhao Y, Li H. Association of serum vitamin C with liver fibrosis in adults with nonalcoholic fatty liver disease. Scand J Gastroenterol. 2022;57:872\u20137. https:\/\/doi.org\/10.1080\/00365521.2022.2041085.","journal-title":"Scand J Gastroenterol"},{"key":"2024_CR20","unstructured":"Centers for Disease Control and Prevention: National Health and Nutrition Examination Survey (NHANES). Interviewer Procedure Manual. 2017-2020. [cited 2025 June]. Avaliable from: https:\/\/wwwn.cdc.gov\/nchs\/data\/nhanes\/public\/2017\/manuals\/2017_Interviewer_Procedures_Manual.pdf."},{"key":"2024_CR21","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1097\/HEP.0000000000000023","volume":"77","author":"E Vilar-Gomez","year":"2023","unstructured":"Vilar-Gomez E, Vuppalanchi R, Gawrieh S, Samala N, Chalasani N. CAP and LSM as determined by VCTE are independent predictors of all-cause mortality in the US adult population. Hepatology. 2023;77:1241\u201352. https:\/\/doi.org\/10.1097\/HEP.0000000000000023.","journal-title":"Hepatology"},{"key":"2024_CR22","doi-asserted-by":"publisher","unstructured":"EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis - 2021 update. J Hepatol 75, 659\u2013689 (2021). https:\/\/doi.org\/10.1016\/j.jhep.2021.05.025","DOI":"10.1016\/j.jhep.2021.05.025"},{"issue":"6","key":"2024_CR23","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1016\/j.jhep.2023.06.003","volume":"79","author":"ME Rinella","year":"2023","unstructured":"Rinella ME, et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. J Hepatol. 2023;79(6):1542\u201356. https:\/\/doi.org\/10.1016\/j.jhep.2023.06.003.","journal-title":"J Hepatol"},{"key":"2024_CR24","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1002\/jpn3.12219","volume":"79","author":"BJ Perumpail","year":"2024","unstructured":"Perumpail BJ, et al. The prevalence and predictors of metabolic dysfunction-associated steatotic liver disease and fibrosis\/cirrhosis among adolescents\/young adults. J Pediatr Gastroenterol Nutr. 2024;79:110\u20138. https:\/\/doi.org\/10.1002\/jpn3.12219.","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"2024_CR25","doi-asserted-by":"publisher","DOI":"10.3350\/cmh.2025.0152","volume":"31","author":"D Kim","year":"2025","unstructured":"Kim D, et al. The burden of steatotic liver disease before and during the COVID-19 pandemic: correspondence to editorial on \u201cCurrent burden of steatotic liver disease and fibrosis among adults in the United States, 2017\u20132023.\u201d Clin Mol Hepatol. 2025;31:e183\u20135. https:\/\/doi.org\/10.3350\/cmh.2025.0152.","journal-title":"Clin Mol Hepatol"},{"key":"2024_CR26","doi-asserted-by":"publisher","first-page":"382","DOI":"10.3350\/cmh.2024.0987","volume":"31","author":"D Kim","year":"2025","unstructured":"Kim D, et al. Current burden of steatotic liver disease and fibrosis among adults in the United States, 2017\u20132023. Clin Mol Hepatol. 2025;31:382\u201393. https:\/\/doi.org\/10.3350\/cmh.2024.0987.","journal-title":"Clin Mol Hepatol"},{"issue":"5","key":"2024_CR27","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1097\/HEP.0000000000001211","volume":"82","author":"A Unalp-Arida","year":"2024","unstructured":"Unalp-Arida A, Ruhl CE. Prevalence of metabolic dysfunction-associated steatotic liver disease and fibrosis defined by liver elastography in the United States using National Health and Nutrition Examination Survey 2017-March 2020 and August 2021-August 2023 data. Hepatology. 2024;82(5):1256\u201373. https:\/\/doi.org\/10.1097\/HEP.0000000000001211.","journal-title":"Hepatology"},{"key":"2024_CR28","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1136\/gutjnl-2020-321611","volume":"69","author":"G Targher","year":"2020","unstructured":"Targher G, et al. Risk of severe illness from COVID-19 in patients with metabolic dysfunction-associated fatty liver disease and increased fibrosis scores. Gut. 2020;69:1545\u20137. https:\/\/doi.org\/10.1136\/gutjnl-2020-321611.","journal-title":"Gut"},{"key":"2024_CR29","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1111\/apt.17547","volume":"58","author":"D Kim","year":"2023","unstructured":"Kim D, et al. Trends in aetiology-based hospitalisation for cirrhosis before and during the COVID-19 pandemic in the United States. Aliment Pharmacol Ther. 2023;58:218\u201328. https:\/\/doi.org\/10.1111\/apt.17547.","journal-title":"Aliment Pharmacol Ther"},{"key":"2024_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2023.100685","volume":"5","author":"L Draijer","year":"2023","unstructured":"Draijer L, et al. A natural history study of paediatric non-alcoholic fatty liver disease over 10 years. JHEP Rep. 2023;5:100685. https:\/\/doi.org\/10.1016\/j.jhepr.2023.100685.","journal-title":"JHEP Rep"},{"key":"2024_CR31","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1002\/hep.20466","volume":"40","author":"JD Browning","year":"2004","unstructured":"Browning JD, et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology. 2004;40:1387\u201395.","journal-title":"Hepatology"},{"issue":"5","key":"2024_CR32","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1097\/MEG.0000000000002741","volume":"36","author":"TH Shen","year":"2024","unstructured":"Shen TH, Wu CH, Lee YW, Chang CC. Prevalence, trends, and characteristics of metabolic dysfunction-associated steatotic liver disease among the US population aged 12-79 years. Eur J Gastroenterol Hepatol. 2024;36(5):636\u201345. https:\/\/doi.org\/10.1097\/MEG.0000000000002741.","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"2024_CR33","doi-asserted-by":"publisher","DOI":"10.1111\/ijpo.70003","volume":"20","author":"M Sun","year":"2025","unstructured":"Sun M, Sun H. Recent prevalence and trends of obesity and metabolic dysfunction-associated steatotic liver disease (MASLD) among US adolescents: 1999 to 2020. Pediatr Obes. 2025;20:e70003. https:\/\/doi.org\/10.1111\/ijpo.70003.","journal-title":"Pediatr Obes"},{"key":"2024_CR34","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1002\/hep.24806","volume":"55","author":"N Santoro","year":"2012","unstructured":"Santoro N, et al. Variant in the glucokinase regulatory protein (GCKR) gene is associated with fatty liver in obese children and adolescents. Hepatology. 2012;55:781\u20139. https:\/\/doi.org\/10.1002\/hep.24806.","journal-title":"Hepatology"},{"key":"2024_CR35","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2013.02.011","author":"R Hernaez","year":"2013","unstructured":"Hernaez R, et al. Association between variants in or near PNPLA3, GCKR, and PPP1R3B with ultrasound-defined steatosis based on data from the third National Health and Nutrition Examination Survey. Clin Gastroenterol Hepatol. 2013. https:\/\/doi.org\/10.1016\/j.cgh.2013.02.011.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2024_CR36","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1002\/hep.28283","volume":"63","author":"M Goffredo","year":"2016","unstructured":"Goffredo M, et al. Role of TM6SF2 rs58542926 in the pathogenesis of nonalcoholic pediatric fatty liver disease: a multiethnic study. Hepatology. 2016;63:117\u201325. https:\/\/doi.org\/10.1002\/hep.28283.","journal-title":"Hepatology"},{"key":"2024_CR37","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1002\/hep.30035","volume":"68","author":"D Tric\u00f2","year":"2018","unstructured":"Tric\u00f2 D, et al. Metabolic features of nonalcoholic fatty liver (NAFL) in obese adolescents: findings from a multiethnic cohort. Hepatology. 2018;68:1376\u201390. https:\/\/doi.org\/10.1002\/hep.30035.","journal-title":"Hepatology"},{"key":"2024_CR38","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1146\/annurev-publhealth-032315-021439","volume":"37","author":"K Fiscella","year":"2016","unstructured":"Fiscella K, Sanders MR. Racial and ethnic disparities in the quality of health care. Annu Rev Public Health. 2016;37:375\u201394. https:\/\/doi.org\/10.1146\/annurev-publhealth-032315-021439.","journal-title":"Annu Rev Public Health"},{"key":"2024_CR39","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmet.2024.101984","volume":"87","author":"AM Buziau","year":"2024","unstructured":"Buziau AM, et al. Hepatic glucokinase regulatory protein and carbohydrate response element binding protein attenuation reduce de novo lipogenesis but do not mitigate intrahepatic triglyceride accumulation in Aldob deficiency. Mol Metab. 2024;87:101984. https:\/\/doi.org\/10.1016\/j.molmet.2024.101984.","journal-title":"Mol Metab"},{"key":"2024_CR40","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1007\/s00431-024-05848-1","volume":"184","author":"A-SR Stroes","year":"2024","unstructured":"Stroes A-SR, Vos M, Benninga MA, Koot BGP. Pediatric MASLD: current understanding and practical approach. Eur J Pediatr. 2024;184:29. https:\/\/doi.org\/10.1007\/s00431-024-05848-1.","journal-title":"Eur J Pediatr"},{"key":"2024_CR41","doi-asserted-by":"publisher","DOI":"10.1186\/1471-230X-6-33","volume":"6","author":"G Bedogni","year":"2006","unstructured":"Bedogni G, Bellentani S, Miglioli L, Masutti F, Passalacqua M, Castiglione A, et al. The fatty liver index: a simple and accurate predictor of hepatic steatosis in the general population. BMC Gastroenterol. 2006;6:33. https:\/\/doi.org\/10.1186\/1471-230X-6-33.","journal-title":"BMC Gastroenterol"},{"issue":"7","key":"2024_CR42","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1016\/j.dld.2009.08.002","volume":"42","author":"JH Lee","year":"2010","unstructured":"Lee JH, et al. Hepatic steatosis index: a simple screening tool reflecting nonalcoholic fatty liver disease. Dig Liver Dis. 2010;42(7):503\u20138. https:\/\/doi.org\/10.1016\/j.dld.2009.08.002.","journal-title":"Dig Liver Dis"},{"key":"2024_CR43","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2025.06.011","author":"K Song","year":"2025","unstructured":"Song K, et al. Optimal cutoffs of fatty liver index and hepatic steatosis index in diagnosing pediatric metabolic dysfunction-associated steatotic liver disease. Clin Gastroenterol Hepatol. 2025. https:\/\/doi.org\/10.1016\/j.cgh.2025.06.011.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"2","key":"2024_CR44","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1097\/MPG.0000000000001482","volume":"64","author":"MB Vos","year":"2017","unstructured":"Vos MB, et al. NASPGHAN clinical practice guideline for the diagnosis and treatment of nonalcoholic fatty liver disease in children: recommendations from the Expert Committee on NAFLD (ECON) and the North American Society of Pediatric Gastroenterology, Hepatology and Nutrition (NASPGHAN). J Pediatr Gastroenterol Nutr. 2017;64(2):319\u201334. https:\/\/doi.org\/10.1097\/MPG.0000000000001482.","journal-title":"J Pediatr Gastroenterol Nutr"},{"issue":"3","key":"2024_CR45","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1210\/jc.2016-2573","volume":"102","author":"DM Styne","year":"2017","unstructured":"Styne DM, et al. Pediatric obesity-assessment, treatment, and prevention: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2017;102(3):709\u201357. https:\/\/doi.org\/10.1210\/jc.2016-2573.","journal-title":"J Clin Endocrinol Metab"},{"key":"2024_CR46","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1111\/apt.70022","volume":"61","author":"SL Noon","year":"2025","unstructured":"Noon SL, et al. Prevalence and predictors of suspected metabolic dysfunction-associated steatotic liver disease in adolescents in the United States. Aliment Pharmacol Ther. 2025;61:1479\u201388. https:\/\/doi.org\/10.1111\/apt.70022.","journal-title":"Aliment Pharmacol Ther"},{"key":"2024_CR47","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1002\/jpn3.12230","volume":"79","author":"N Ma","year":"2024","unstructured":"Ma N, Bansal M, Chu J, Branch AD. Fibrosis and steatotic liver disease in US adolescents according to the new nomenclature. J Pediatr Gastroenterol Nutr. 2024;79:229\u201337. https:\/\/doi.org\/10.1002\/jpn3.12230.","journal-title":"J Pediatr Gastroenterol Nutr"},{"issue":"5","key":"2024_CR48","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1016\/j.jhep.2021.06.034","volume":"75","author":"TG Simon","year":"2021","unstructured":"Simon TG, et al. Non-alcoholic fatty liver disease in children and young adults is associated with increased long-term mortality. J Hepatol. 2021;75(5):1034\u201341. https:\/\/doi.org\/10.1016\/j.jhep.2021.06.034.","journal-title":"J Hepatol"},{"key":"2024_CR49","doi-asserted-by":"publisher","DOI":"10.3350\/cmh.2024.0246","author":"Y Wang","year":"2024","unstructured":"Wang Y, et al. Role of noninvasive tests in the prognostication of metabolic dysfunction-associated steatotic liver disease. Clin Mol Hepatol. 2024. https:\/\/doi.org\/10.3350\/cmh.2024.0246.","journal-title":"Clin Mol Hepatol"},{"key":"2024_CR50","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1002\/hep.22376","volume":"48","author":"V Nobili","year":"2008","unstructured":"Nobili V, et al. Accuracy and reproducibility of transient elastography for the diagnosis of fibrosis in pediatric nonalcoholic steatohepatitis. Hepatology. 2008;48:442\u20138. https:\/\/doi.org\/10.1002\/hep.22376.","journal-title":"Hepatology"}],"container-title":["Diabetology &amp; Metabolic Syndrome"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13098-025-02024-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13098-025-02024-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13098-025-02024-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T00:34:18Z","timestamp":1767054858000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13098-025-02024-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,30]]},"references-count":50,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2024"],"URL":"https:\/\/doi.org\/10.1186\/s13098-025-02024-9","relation":{},"ISSN":["1758-5996"],"issn-type":[{"value":"1758-5996","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,30]]},"assertion":[{"value":"4 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Since the data adopted in this study were all publicly available data from the NHANES, all data related studies were approved by their respective ethical review committees and received written informed consent from patients. Therefore, this study does not need additional ethics approval.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"462"}}